Home > Neurology > MS Virtual 2020 > Treatment Strategies and Results > Safety and efficacy of dimethyl fumarate: 13 years of follow-up

Safety and efficacy of dimethyl fumarate: 13 years of follow-up


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
MS Virtual 2020
Trial
ENDORSE, DEFINE, CONFIRM
The overall benefit-risk ratio of dimethyl fumarate (DMF) remained favourable during a 13-year follow-up period [1]. Low rates of relapse were sustained throughout the 10-year treatment period. Rates of confirmed disability progression, serious infections, and malignancies were also low. The final safety and efficacy results of DMF 240 mg twice daily (the approved dosage) were reported in patients with relapsing-remitting MS who were followed for 13 years in the ENDORSE trial (2 years DEFINE/CONFIRM and >10 years in ENDORSE). Patients were either treated with placebo in year 0-2 followed by DMF in year 3-10 (PBO/DMF) or with DMF continuously (DMF/...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on